Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario
← catalyst calendarNCT02177721 · readout ≤ 3,207 d
Sponsored by Emergent BioSolutions (industry) · EBS — their whole pipeline →. With Centers for Disease Control and Prevention, Biomedical Advanced Research and Development Authority.
Phase
Phase 4
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
100estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jan 2027 | estimated | When the study began enrolling |
| Primary completion | May 2035 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2035 | estimated | The whole study's end, after follow-up |
| First posted | 2014-06-30 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Infections, Bacterial
Intervention
- Biological: Sample Collection
Primary outcome
what the primary-completion date above is the date OFEvaluate Clinical Benefit of Raxibacumab for Patients with Symptomatic Inhalational Anthrax
measured Up to Day 29
Permalink · EBS's whole pipeline · Catalyst calendar · Every registered study · What changed